Table 3 Prevalence of RR-TB among MTB positive patients at the UoGCSH (2015 – 2021)
Variables | Frequency No (%) | Rifampicin resistance | Chi-square (X2) | p-value | ||
|---|---|---|---|---|---|---|
Detected No (%) | Not detected No (%) | |||||
Sex (n = 1846) | Male | 1060 (57.4) | 73 (6.9) | 987 (93.1) | 1.036 | 0.309 |
Female | 786 (42.6) | 64 (8.1) | 722 (91.9) | |||
Age in years (n = 1846) | ≤ 5 | 39 (2.1) | 0 | 39 (100) | 14.551 | 0.024 |
6 – 15 | 66 (3.6) | 4 (6.1) | 62 (93.9) | |||
16 – 25 | 498 (27.0) | 35 (7.0) | 463 (93.0) | |||
26 – 35 | 572 (31.0) | 38 (6.6) | 534 (93.4) | |||
36 – 45 | 331 (17.9) | 24 (7.3) | 307 (92.7) | |||
46 – 55 | 163 (8.8) | 23 (14.1) | 140 (85.9) | |||
≥ 56 | 177 (9.6) | 13 (7.3) | 164 (92.7) | |||
Year of diagnosis (n = 1846) | 2015 | 395 (21.4) | 45 (11.4) | 350 (88.6) | 18.287 | 0.006 |
2016 | 230 (12.5) | 16 (7.0) | 214 (93.0) | |||
2017 | 275 (14.9) | 21 (7.6) | 254 (92.4) | |||
2018 | 132 (7.2) | 8 (6.1) | 124 (93.9) | |||
2019 | 193 (10.5) | 18 (9.3) | 175 (90.7) | |||
2020 | 235 (12.7) | 14 (6.0) | 221 (94.0) | |||
2021 | 386 (20.9) | 15 (3.9) | 371 (96.1) | |||
TB category (n = 622) | New | 471 (75.7) | 40 (8.5) | 431 (91.5) | 11.862 | < 0.001 |
Re-Rx | 151 (24.3) | 28 (18.5) | 123 (81.5) | |||
HIV status (n = 466) | Positive | 182 (39.0) | 11 (6.0) | 171 (94.0) | 1.469 | 0.226 |
Negative | 284 (61.0) | 26 (9.2) | 258 (90.8) | |||
Specimen type (n = 1783) | Sputum | 1718 (96.4) | 131 (7.6) | 1587 (92.4) | 3.214 | 0.200 |
Gas-aspir | 39 (2.2) | 0 | 39 (100) | |||
Others | 26 (1.5) | 2 (7.7) | 24 (92.3) | |||
Diagnosis (n = 1783) | PTB | 1757 (98.5) | 131 (7.5) | 1626 (92.5) | 0.002 | 0.964 |
EPTB | 26 (1.5) | 2 (7.7) | 24 (92.3) | |||
Refer-unit (n = 1541) | UoGCSH | 1292 (83.8) | 87 (6.7) | 1205 (93.3) | 1.403 | 0.236 |
HCs | 249 (16.2) | 22 (8.8) | 227 (91.2) | |||